D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Biology and Biochemistry D-index 44 Citations 6,014 117 World Ranking 13501 National Ranking 5736

Overview

What is he best known for?

The fields of study he is best known for:

  • DNA
  • Immune system
  • Cancer

His main research concerns Oligonucleotide, Molecular biology, CpG site, Cancer research and Biochemistry. His Oligonucleotide research includes themes of Combinatorial chemistry and Stereochemistry. Ekambar R. Kandimalla has researched Molecular biology in several fields, including Receptor, Peripheral blood mononuclear cell and Cytokine secretion, Immune system.

His work carried out in the field of Receptor brings together such families of science as DNA sequencing and Cell biology. The concepts of his Cancer research study are interwoven with issues in Cancer cell, XIAP and Apoptosis. His study in Biochemistry is interdisciplinary in nature, drawing from both Immune Stimulation and Immunostimulant.

His most cited work include:

  • Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds by Optimal Presentation of 5' Ends (207 citations)
  • Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. (165 citations)
  • Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles (147 citations)

What are the main themes of his work throughout his whole career to date?

Ekambar R. Kandimalla spends much of his time researching Oligonucleotide, Immunology, Molecular biology, Immune system and Receptor. His work in Oligonucleotide tackles topics such as Stereochemistry which are related to areas like Hydrogen bond. While working on this project, Ekambar R. Kandimalla studies both Molecular biology and CpG site.

He works mostly in the field of Immune system, limiting it down to concerns involving Agonist and, occasionally, Cancer research and Tumor microenvironment. His studies deal with areas such as Toll and Cell biology as well as Receptor. His DNA study incorporates themes from RNase H and Circular dichroism.

He most often published in these fields:

  • Oligonucleotide (32.45%)
  • Immunology (23.84%)
  • Molecular biology (23.18%)

What were the highlights of his more recent work (between 2011-2020)?

  • Immunology (23.84%)
  • Antagonist (7.28%)
  • Internal medicine (9.93%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Immunology, Antagonist, Internal medicine, Agonist and Receptor. His work deals with themes such as mdx mouse, Duchenne muscular dystrophy, Dystrophin, Skeletal muscle and Cell biology, which intersect with Immunology. His Cell biology study combines topics from a wide range of disciplines, such as Biochemistry and Antisense Agents.

His Antagonist research is multidisciplinary, incorporating elements of TLR7 and Stimulation. His work in Agonist covers topics such as Tumor microenvironment which are related to areas like Cancer research and CD8. His study looks at the relationship between Receptor and fields such as Inflammation, as well as how they intersect with chemical problems.

Between 2011 and 2020, his most popular works were:

  • Inhibition of 14q32 MicroRNAs miR-329, miR-487b, miR-494 and miR-495 Increases Neovascularization and Blood Flow Recovery after Ischemia (90 citations)
  • Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9 (72 citations)
  • A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice (53 citations)

In his most recent research, the most cited papers focused on:

  • DNA
  • Immune system
  • Cancer

His scientific interests lie mostly in Immunology, Receptor, Antagonist, Agonist and TLR9. The study incorporates disciplines such as Dystrophin and ITGA7 in addition to Immunology. His Receptor research incorporates elements of Inflammation and Endocrinology.

The Antagonist study combines topics in areas such as TLR7 and Psoriasis. Ekambar R. Kandimalla has included themes like Clonogenic assay, Gastrointestinal tract, Systemic administration and Crypt in his Agonist study. His TLR9 study spans across into areas like In vivo, Interleukin, Molecular biology, Interferon and Cytokine.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics.

Dan C McManus;Charles A Lefebvre;Gabriele Cherton-Horvat;Martine St-Jean.
Oncogene (2004)

255 Citations

Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds by Optimal Presentation of 5' Ends

Sudhir Agrawal;Ekambar R. Kandimalla;Dong Yu;Lakshmi Bhagat.
(2002)

229 Citations

Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles

Ekambar R. Kandimalla;Lakshmi Bhagat;Daqing Wang;Dong Yu.
Nucleic Acids Research (2003)

224 Citations

Immunomodulatory oligonucleotides containing a cytosine-phosphate-2′-deoxy-7-deazaguanosine motif as potent Toll-like receptor 9 agonists

Ekambar R. Kandimalla;Lakshmi Bhagat;Yukui Li;Dong Yu.
Proceedings of the National Academy of Sciences of the United States of America (2005)

193 Citations

Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships.

Ekambar R Kandimalla;Dong Yu;Qiuyan Zhao;Sudhir Agrawal.
Bioorganic & Medicinal Chemistry (2001)

166 Citations

Preclinical Characterization of AEG35156/GEM 640, a Second-Generation Antisense Oligonucleotide Targeting X-Linked Inhibitor of Apoptosis

Eric C. LaCasse;Gabriele G. Cherton-Horvat;Kimberley E. Hewitt;Lori J. Jerome.
Clinical Cancer Research (2006)

165 Citations

Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways.

Sai Latha Shankar;Sridhar Mani;Kathleen Norman O'Guin;Ekambar R. Kandimalla.
Journal of Neurochemistry (2008)

160 Citations

Medicinal chemistry and therapeutic potential of CpG DNA

Sudhir Agrawal;Ekambar R Kandimalla.
Trends in Molecular Medicine (2002)

153 Citations

Antisense and siRNA as agonists of Toll-like receptors

Sudhir Agrawal;Ekambar R Kandimalla.
Nature Biotechnology (2004)

151 Citations

Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity.

Ekambar R Kandimalla;Lakshmi Bhagat;Dong Yu;Yanping Cong.
Bioconjugate Chemistry (2002)

145 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Ekambar R. Kandimalla

Arthur M. Krieg

Arthur M. Krieg

Pfizer (United States)

Publications: 38

Antonin de Fougerolles

Antonin de Fougerolles

Alnylam Pharmaceuticals (United States)

Publications: 26

Sudhir Agrawal

Sudhir Agrawal

University of Massachusetts Medical School

Publications: 22

Simone Fulda

Simone Fulda

Goethe University Frankfurt

Publications: 20

Gennaro Ciliberto

Gennaro Ciliberto

Magna Graecia University

Publications: 17

Giampaolo Tortora

Giampaolo Tortora

University of Verona

Publications: 15

Shizuo Akira

Shizuo Akira

Osaka University

Publications: 13

Hui Wang

Hui Wang

Chinese Academy of Sciences

Publications: 11

Eicke Latz

Eicke Latz

University of Bonn

Publications: 11

Ramon Eritja

Ramon Eritja

Spanish National Research Council

Publications: 11

Rino Rappuoli

Rino Rappuoli

Imperial College London

Publications: 10

Fortunato Ciardiello

Fortunato Ciardiello

University of Campania "Luigi Vanvitelli"

Publications: 9

Masad J. Damha

Masad J. Damha

McGill University

Publications: 9

Makiya Nishikawa

Makiya Nishikawa

Tokyo University of Science

Publications: 9

Guido Grandi

Guido Grandi

University of Trento

Publications: 9

Grayson B. Lipford

Grayson B. Lipford

Janus Biotherapeutics (United States)

Publications: 8

Trending Scientists

Paul Clough

Paul Clough

University of Sheffield

Horst Simon

Horst Simon

Lawrence Berkeley National Laboratory

Thomas D. Willett

Thomas D. Willett

Claremont Graduate University

Hongli Dong

Hongli Dong

Northeast Petroleum University

Richard R. Hofer

Richard R. Hofer

NASA Jet Propulsion Laboratory

Diego J. Ramón

Diego J. Ramón

University of Alicante

Fereidoun Rassoulzadegan

Fereidoun Rassoulzadegan

Centre national de la recherche scientifique, CNRS

Marc D. Abrams

Marc D. Abrams

Pennsylvania State University

Steven T. Koike

Steven T. Koike

University of California, Berkeley

Lajos Kemény

Lajos Kemény

University of Szeged

Odd-Arne Olsen

Odd-Arne Olsen

Norwegian University of Life Sciences

Weijun Li

Weijun Li

Zhejiang University

Jose L. Sericano

Jose L. Sericano

Texas A&M University

Roger Perry

Roger Perry

Imperial College London

Sharon Dawe

Sharon Dawe

Griffith University

Robert Howse

Robert Howse

New York University

Something went wrong. Please try again later.